This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial). | MicrobiomeTrials
← Back to trials NCT05895136
A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial). Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2024-07-01Est. Completion: 2026-10-31
Enrollment target: 90 participantsLocations Hôpital Beaujon, Clichy, France Universitätsklinikum Aachen AöR, Aachen, Germany Universität Münster, Münster, Germany IRCSS Azienda Ospedaliero Universitaria di Bologna Policlinico di Sant'Orsola, Bologna, Emilia-Romagna, Italy Azienda Ospedaliero-Universitaria "Città della Salute e della Scienza di Torino", Turin, Piedmont, Italy Hospital Universitari Vall d'Hebron-VHIR, Barcelona, Spain Hospital Clínic de Barcelona-FCRB, Barcelona, Spain Hospital Universitario Ramón y Cajal, Madrid, Spain Royal Free Hospital, London, United Kingdom Other microbiome trials you might be interested in Carcinoma, Hepatocellular Cirrhosis, Liver
Clinical guidelines (AASLD) recommend the use of abdominal ultrasound (US) for surveillance testing for the early detect…
Los Angeles, United States Est. completion Aug 25, 2023
Cirrhoses, Liver
Hepatic decompensation is a common healthcare issue
. This study was conducted to investigate how allopurinol can inter…
Tanta, Egypt Completed Mar 1, 2024
Hematopoietic Stem Cell Transplant
Background:
Hematopoietic stem cell transplant (HSCT) is a common treatment for many cancers and other illnesses. But m…
Bethesda, United States Est. completion Jun 30, 2031